Related Experiment Video

Updated: Mar 28, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K

[Advanced Research on MicroRNAs and EGFR-TKIs Secondary Resistance]

Ming Wang1, Zhenyu Sun2, Linian Huang3

  • 1Bengbu Medical College, Bengbu 233000, China;Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Bengbu Medical College, Bengbu 233000, China.

Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer
|December 29, 2015
PubMed

Insights

MicroRNAs (miRNAs) are linked to drug resistance in non-small cell lung cancer (NSCLC) treated with epidermal growth factor receptor (EGFR) inhibitors. Targeting miRNAs may overcome resistance and predict treatment success.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Lung cancer is a major global cause of cancer mortality.
  • The epidermal growth factor receptor (EGFR) pathway is crucial in lung cancer development.
  • EGFR-tyrosine kinase inhibitors (EGFR-TKIs) are used for non-small cell lung cancer (NSCLC) with EGFR mutations.

Purpose of the Study:

  • To review the role of microRNAs (miRNAs) in acquired resistance to EGFR-TKIs in NSCLC.
  • To explore miRNAs as potential therapeutic targets and predictive biomarkers for EGFR-TKI resistance.

Main Methods:

  • Literature review of recent research on miRNAs and EGFR-TKI resistance in NSCLC.
  • Analysis of studies investigating the correlation between miRNA expression and drug resistance.

Main Results:

  • Acquired resistance to EGFR-TKIs is a significant clinical challenge in NSCLC treatment.
  • MiRNAs are increasingly recognized for their involvement in the mechanisms of EGFR-TKI secondary resistance.
  • Evidence suggests miRNAs can modulate sensitivity to EGFR-TKIs.

Conclusions:

  • MiRNAs represent promising novel targets to overcome EGFR-TKI resistance in NSCLC.
  • MiRNAs may serve as valuable predictive biomarkers for patient response to EGFR-TKIs.
  • Further research into miRNA-based strategies is warranted for improved NSCLC therapy.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.5K
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

11.3K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.3K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.6K